Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 110

1.

Alloanergization of human T cells results in expansion of alloantigen-specific CD8(+) CD28(-) suppressor cells.

Barbon CM, Davies JK, Voskertchian A, Kelner RH, Brennan LL, Nadler LM, Guinan EC.

Am J Transplant. 2014 Feb;14(2):305-18. doi: 10.1111/ajt.12575. Epub 2014 Jan 10.

2.

Ex vivo alloanergization with belatacept: a strategy to selectively modulate alloresponses after transplantation.

Davies JK, Barbon CM, Voskertchian A, Nadler LM, Guinan EC.

Cell Transplant. 2012;21(9):2047-61. doi: 10.3727/096368912X637479. Epub 2012 Apr 10.

PMID:
22507909
3.

Induction of alloantigen-specific anergy in human peripheral blood mononuclear cells by alloantigen stimulation with co-stimulatory signal blockade.

Davies JK, Barbon CM, Voskertchian AR, Nadler LM, Guinan EC.

J Vis Exp. 2011 Mar 14;(49). pii: 2673. doi: 10.3791/2673.

4.

Induction of alloanergy in human donor T cells without loss of pathogen or tumor immunity.

Davies JK, Yuk D, Nadler LM, Guinan EC.

Transplantation. 2008 Sep 27;86(6):854-64. doi: 10.1097/TP.0b013e3181861b6c. Erratum in: Transplantation. 2012 Jun 15;93(11):e44. Dosage error in article text.

5.

CTLA-4 engagement and regulatory CD4+CD25+ T cells independently control CD8+-mediated responses under costimulation blockade.

Coenen JJ, Koenen HJ, van Rijssen E, Boon L, Joosten I, Hilbrands LB.

J Immunol. 2006 May 1;176(9):5240-6.

6.
7.

Human CD34(+) blood cells induce T-cell unresponsiveness to specific alloantigens only under costimulatory blockade.

Arpinati M, Terragna C, Chirumbolo G, Rizzi S, Urbini B, Re F, Tura S, Baccarani M, Rondelli D.

Exp Hematol. 2003 Jan;31(1):31-8.

PMID:
12543104
8.
9.

Overlap between molecular markers expressed by naturally occurring CD4+CD25+ regulatory T cells and antigen specific CD4+CD25+ and CD8+CD28- T suppressor cells.

Scotto L, Naiyer AJ, Galluzzo S, Rossi P, Manavalan JS, Kim-Schulze S, Fang J, Favera RD, Cortesini R, Suciu-Foca N.

Hum Immunol. 2004 Nov;65(11):1297-306.

PMID:
15556680
10.

On CD28/CD40 ligand costimulation, common gamma-chain signals, and the alloimmune response.

Demirci G, Gao W, Zheng XX, Malek TR, Strom TB, Li XC.

J Immunol. 2002 May 1;168(9):4382-90.

11.

Analysis of the role of negative T cell costimulatory pathways in CD4 and CD8 T cell-mediated alloimmune responses in vivo.

Ito T, Ueno T, Clarkson MR, Yuan X, Jurewicz MM, Yagita H, Azuma M, Sharpe AH, Auchincloss H Jr, Sayegh MH, Najafian N.

J Immunol. 2005 Jun 1;174(11):6648-56.

12.
13.

Nonantigen specific CD8+ T suppressor lymphocytes originate from CD8+CD28- T cells and inhibit both T-cell proliferation and CTL function.

Filaci G, Fravega M, Negrini S, Procopio F, Fenoglio D, Rizzi M, Brenci S, Contini P, Olive D, Ghio M, Setti M, Accolla RS, Puppo F, Indiveri F.

Hum Immunol. 2004 Feb;65(2):142-56.

PMID:
14969769
14.

A novel alloantigen-specific CD8+PD1+ regulatory T cell induced by ICOS-B7h blockade in vivo.

Izawa A, Yamaura K, Albin MJ, Jurewicz M, Tanaka K, Clarkson MR, Ueno T, Habicht A, Freeman GJ, Yagita H, Abdi R, Pearson T, Greiner DL, Sayegh MH, Najafian N.

J Immunol. 2007 Jul 15;179(2):786-96.

15.

T helper-independent activation of human CD8+ cells: the role of CD28 costimulation.

Van Gool SW, Zhang Y, Kasran A, de Boer M, Ceuppens JL.

Scand J Immunol. 1996 Jul;44(1):21-9.

PMID:
8693288
16.

Inducible costimulator (ICOS) up-regulation on activated T cells in chronic graft-versus-host disease after dog leukocyte antigen-nonidentical hematopoietic cell transplantation: a potential therapeutic target.

Sato M, Storb R, Loretz C, Stone D, Mielcarek M, Sale GE, Rezvani AR, Graves SS.

Transplantation. 2013 Jul 15;96(1):34-41. doi: 10.1097/TP.0b013e318295c025.

17.

Efficient induction and expansion of human alloantigen-specific CD8 regulatory T cells from naive precursors by CD40-activated B cells.

Zheng J, Liu Y, Qin G, Chan PL, Mao H, Lam KT, Lewis DB, Lau YL, Tu W.

J Immunol. 2009 Sep 15;183(6):3742-50. doi: 10.4049/jimmunol.0901329. Epub 2009 Aug 14.

18.

Alloantigen specific CD8+CD28- FOXP3+ T suppressor cells induce ILT3+ ILT4+ tolerogenic endothelial cells, inhibiting alloreactivity.

Manavalan JS, Kim-Schulze S, Scotto L, Naiyer AJ, Vlad G, Colombo PC, Marboe C, Mancini D, Cortesini R, Suciu-Foca N.

Int Immunol. 2004 Aug;16(8):1055-68. Epub 2004 Jun 28.

19.
20.

Combining CD19 redirection and alloanergization to generate tumor-specific human T cells for allogeneic cell therapy of B-cell malignancies.

Davies JK, Singh H, Huls H, Yuk D, Lee DA, Kebriaei P, Champlin RE, Nadler LM, Guinan EC, Cooper LJ.

Cancer Res. 2010 May 15;70(10):3915-24. doi: 10.1158/0008-5472.CAN-09-3845. Epub 2010 Apr 27.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk